ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
Variants in
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 5 pooled it
6.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 5 syntheses or guidelines pooled it, 80 citations in OpenAlex.
- Ototoxicity prognostic models in adult and pediatric cancer patients: a rapid review.Journal of cancer survivorship : research and practice · 2023Pooled it
- Family Socioeconomic Position and Lung Cancer Risk: A Meta-Analysis and a Mendelian Randomization Study.Frontiers in public health · 2022Pooled it
- The genetic vulnerability to cisplatin ototoxicity: a systematic review.Scientific reports · 2019Pooled it
- Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes.Clinical pharmacology and therapeutics · 2019Pooled it
- Long-term toxicity of cisplatin in germ-cell tumor survivors.Annals of oncology : official journal of the European Society for Medical Oncology · 2017Pooled it
- Navigating the Genetic Risk of Chemotherapy-Induced Hearing Loss in the Stria Vascularis.Clinical pharmacology and therapeutics · 2026Review
- Inherited immune traits and cisplatin-induced ototoxicity in cancer patients: a Mendelian randomization study.International journal of clinical pharmacy · 2026Article
- Article
- Impact of Population Pharmacogenomics on Cisplatin-Induced Neurotoxicities in Testicular Cancer Survivors.Cancer medicine · 2025Article
- Identification of Risk Loci for Radiotherapy-Induced Tinnitus and Hearing Loss Through Integrated Genomic Analysis.International journal of molecular sciences · 2025Article
- Strategies to Mitigate Cisplatin-Induced Ototoxicity: A Literature Review of Protective Agents, Mechanisms, and Clinical Gaps.Audiology research · 2025Review
- Leveraging large-scale datasets and single cell omics data to develop a polygenic score for cisplatin-induced ototoxicity.Human genomics · 2024Article
- The role of genetic variants in the prediction of hearing loss due to cisplatin chemoradiotherapy.Cancer medicine · 2024Article
- Loss of Fascin2 increases susceptibility to cisplatin-induced hearing impairment and cochlear cell apoptosis in mice.Journal of otology · 2024Article
- Prediction of Tumor Microenvironment Characteristics and Treatment Response in Lung Squamous Cell Carcinoma by Pseudogene OR7E47P-related Immune Genes.Current medical science · 2023Article
- Predicting Hearing Loss in Testicular Cancer Patients after Cisplatin-Based Chemotherapy.Cancers · 2023Article
- Clinical and genome-wide association analysis of chemoradiation-induced hearing loss in nasopharyngeal carcinoma.Human genetics · 2023Article
- Article
- Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathy.Cancer medicine · 2022Article
- Modern developments in germline pharmacogenomics for oncology prescribing.CA: a cancer journal for clinicians · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 2 institutions in 1 country.
Heather E WheelerDepartment of Biology, Loyola University Chicago, Chicago, Illinois.
Eric R GamazonDivision of Genetic Medicine, Vanderbilt University, Nashville, Tennessee.
Robert D FrisinaDepartment of Chemical and Biomedical Engineering, University of South Florida, Tampa, Florida.
Carlos Perez-CervantesDepartment of Biology, Loyola University Chicago, Chicago, Illinois.
Omar El CharifDepartment of Medicine, University of Chicago, Chicago, Illinois.
Brandon MapesDepartment of Medicine, University of Chicago, Chicago, Illinois.
Sophie D FossaDepartment of Oncology, Oslo University Hospital, Radiumhospital, Oslo, Norway.
Darren R FeldmanDepartment of Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York.
Robert J HamiltonDepartment of Surgical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
David J VaughnDepartment of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Clair J BeardDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Chunkit FungJ.P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York.
Christian KollmannsbergerDivision of Medical Oncology, University of British Columbia, Vancouver, British Columbia, Canada.
Jeri KimDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Taisei MushirodaRIKEN Center for Integrative Medical Science, Yokohama, Japan.
Michiaki KuboRIKEN Center for Integrative Medical Science, Yokohama, Japan.
Shirin Ardeshir-Rouhani-FardDepartment of Medical Oncology, Indiana University, Indianapolis, Indiana.
Lawrence H EinhornDepartment of Medical Oncology, Indiana University, Indianapolis, Indiana. leinhorn@iupui.edu.
Nancy J CoxDivision of Genetic Medicine, Vanderbilt University, Nashville, Tennessee.
M Eileen DolanDepartment of Medicine, University of Chicago, Chicago, Illinois.
Lois B TravisDepartment of Medical Oncology, Indiana University, Indianapolis, Indiana.
University of Chicago · USUniversity of South Florida · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MPharmacogenomics of Membrane TransportersU19GM061390 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KWOK, PUI-YAN · 2010 to 2014
$16.3MGenetic Susceptibility and Biomarkers of Platinum-related ToxicitiesR01CA157823 · NCI · UNIVERSITY OF ROCHESTER · PI TRAVIS, LOIS B. · 2012 to 2025
$11.2MModeling the temporal succession of phenotypes & environnnental cuesP50MH094267 · NIMH · UNIVERSITY OF CHICAGO · PI RZHETSKY, ANDREY · 2011 to 2015
$10.2MHarnessing GTEx to Create Transcriptome Knowledge and Inform Disease BiologyR01MH101820 · NIMH · UNIVERSITY OF CHICAGO · PI COX, NANCY J, NICOLAE, DAN LIVIU · 2013 to 2015
$2.3MUsing the Transcriptome for SNP and Gene AnnotationR01MH090937 · NIMH · UNIVERSITY OF CHICAGO · PI COX, NANCY J, NICOLAE, DAN LIVIU · 2010 to 2012
$825kNCI NIH HHS P30 CA008748NCI NIH HHS R01 CA157823NIGMS NIH HHS U19 GM061390NIMH NIH HHS P50 MH094267NIMH NIH HHS R01 MH090937NIMH NIH HHS R01 MH101820
Abstract
PubMed holds no abstract for this paper.
Indexed as
Antineoplastic AgentsCisplatinFemaleGenome-Wide Association StudyGenotypeHearing LossHumansMaleMembrane ProteinsPolymorphism, Single NucleotideTesticular NeoplasmsAntineoplastic AgentsCisplatinMembrane Proteinswolframin protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.